IN2014DN05869A - - Google Patents
Info
- Publication number
- IN2014DN05869A IN2014DN05869A IN5869DEN2014A IN2014DN05869A IN 2014DN05869 A IN2014DN05869 A IN 2014DN05869A IN 5869DEN2014 A IN5869DEN2014 A IN 5869DEN2014A IN 2014DN05869 A IN2014DN05869 A IN 2014DN05869A
- Authority
- IN
- India
- Prior art keywords
- tautomer
- compounds
- pharmaceutically acceptable
- acceptable salt
- combination
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 229960002258 fulvestrant Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960004622 raloxifene Drugs 0.000 abstract 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 abstract 1
- 229960002119 raloxifene hydrochloride Drugs 0.000 abstract 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
- 229960005026 toremifene Drugs 0.000 abstract 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593047P | 2012-01-31 | 2012-01-31 | |
| PCT/US2013/023781 WO2013116293A1 (en) | 2012-01-31 | 2013-01-30 | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05869A true IN2014DN05869A (fi) | 2015-05-22 |
Family
ID=47679114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5869DEN2014 IN2014DN05869A (fi) | 2012-01-31 | 2013-01-30 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140378422A1 (fi) |
| EP (1) | EP2809312A1 (fi) |
| JP (1) | JP2015505562A (fi) |
| KR (1) | KR20140117457A (fi) |
| CN (1) | CN104093402A (fi) |
| AU (1) | AU2013215251A1 (fi) |
| BR (1) | BR112014017985A8 (fi) |
| CA (1) | CA2861377A1 (fi) |
| IN (1) | IN2014DN05869A (fi) |
| MX (1) | MX2014009303A (fi) |
| RU (1) | RU2014135436A (fi) |
| WO (1) | WO2013116293A1 (fi) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201607334YA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| US10118910B2 (en) * | 2015-12-09 | 2018-11-06 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| AU2017226389B2 (en) | 2016-03-04 | 2023-02-02 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| TWI823845B (zh) | 2017-01-06 | 2023-12-01 | 美商G1治療公司 | 用於治療癌症的組合療法 |
| CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| EP3737377A1 (en) | 2018-01-10 | 2020-11-18 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| EP3769765B1 (en) | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| AU2019241625A1 (en) | 2018-03-28 | 2020-09-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| JP7441213B2 (ja) * | 2018-09-13 | 2024-02-29 | ゼニス・エピジェネティクス・リミテッド | エストロゲン受容体陽性乳癌の治療のための併用療法 |
| WO2020110974A1 (ja) * | 2018-11-26 | 2020-06-04 | 大鵬薬品工業株式会社 | 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法 |
| TW202220652A (zh) * | 2020-07-31 | 2022-06-01 | 日商衛材R&D企管股份有限公司 | 乳癌治療劑 |
| BR112023017116A2 (pt) * | 2021-03-03 | 2023-09-26 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Composição farmacêutica combinada contendo inibidor de cdk4/6 e uso da mesma |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (fi) | 1962-09-13 | |||
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| ATE386736T1 (de) | 2000-09-11 | 2008-03-15 | Novartis Vaccines & Diagnostic | Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| ITTV20030095A1 (it) | 2003-07-14 | 2005-01-15 | Asolo Spa | Calzatura con sottopiede composito. |
| CN102225926A (zh) | 2003-11-07 | 2011-10-26 | 诺华疫苗和诊断公司 | 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐 |
| PL1845990T3 (pl) * | 2005-01-27 | 2012-02-29 | Novartis Vaccines & Diagnostics Inc | Leczenie guzów z przerzutami |
| DK1885187T3 (da) * | 2005-05-13 | 2013-12-09 | Novartis Ag | Fremgangsmåde til behandling af lægemiddelresistent cancer |
| CN102070614B (zh) | 2005-05-23 | 2014-01-15 | 诺华股份有限公司 | 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式 |
| TW200730176A (en) | 2005-11-29 | 2007-08-16 | Novartis Ag | Formulations of quinolinones |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
-
2013
- 2013-01-30 WO PCT/US2013/023781 patent/WO2013116293A1/en active Application Filing
- 2013-01-30 RU RU2014135436A patent/RU2014135436A/ru unknown
- 2013-01-30 US US14/375,145 patent/US20140378422A1/en not_active Abandoned
- 2013-01-30 IN IN5869DEN2014 patent/IN2014DN05869A/en unknown
- 2013-01-30 EP EP13703295.9A patent/EP2809312A1/en not_active Withdrawn
- 2013-01-30 MX MX2014009303A patent/MX2014009303A/es unknown
- 2013-01-30 KR KR1020147021140A patent/KR20140117457A/ko not_active Application Discontinuation
- 2013-01-30 BR BR112014017985A patent/BR112014017985A8/pt not_active Application Discontinuation
- 2013-01-30 AU AU2013215251A patent/AU2013215251A1/en not_active Abandoned
- 2013-01-30 JP JP2014555661A patent/JP2015505562A/ja active Pending
- 2013-01-30 CN CN201380006947.7A patent/CN104093402A/zh active Pending
- 2013-01-30 CA CA2861377A patent/CA2861377A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013215251A1 (en) | 2014-08-14 |
| EP2809312A1 (en) | 2014-12-10 |
| RU2014135436A (ru) | 2016-03-27 |
| BR112014017985A8 (pt) | 2017-07-11 |
| MX2014009303A (es) | 2014-10-14 |
| CA2861377A1 (en) | 2013-08-08 |
| BR112014017985A2 (fi) | 2017-06-20 |
| CN104093402A (zh) | 2014-10-08 |
| US20140378422A1 (en) | 2014-12-25 |
| KR20140117457A (ko) | 2014-10-07 |
| JP2015505562A (ja) | 2015-02-23 |
| WO2013116293A1 (en) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05869A (fi) | ||
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| PH12013501341A1 (en) | Morphinan compounds | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
| EA201101507A1 (ru) | Способы лечения солидных опухолей | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| PH12017501294A1 (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
| TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| EA201490573A1 (ru) | Соединение бензотиазолона |